Lodoxamide

From WikiProjectMed
Jump to navigation Jump to search
Lodoxamide
Lodoxamide structure.png
Names
  • N,N′-(2-Chloro-5-cyano-1,3-phenylene)dioxamic acid
Clinical data
Drug classMast cell stabilizer[1]
Main usesAllergic conjunctivitis[2]
Side effectsEye discomfort, dry eyes[1][2]
Typical dose1 to 2 drops QID[1]
External links
AHFS/Drugs.comMonograph
US NLMLodoxamide
Chemical and physical data
FormulaC11H6ClN3O6
Molar mass311.63 g·mol−1

Lodoxamide, sold under the brand name Alomide among others, is a medication used to treat allergic conjunctivitis.[2] It is used as an eye drop.[1] It may be used in children over the age of 2 years.[1]

Common side effects may include eye discomfort and dry eyes.[1][2] Use in pregnancy appears to be safe but such use has not been well studied.[3] It is a mast cell stabilizer.[1]

Lodoxamide was approved for medical use in the United States in 1993.[1] In the United Kingdom a 10 ml bottle costs the NHS about £5 as of 2021.[2] In the United States this amount costs about 175 USD.[4]

Research

In 2014 lodoxamide and bufrolin were found to be potent agonists at the G protein-coupled receptor 35, an orphan receptor believed to play a role in inflammatory processes, pain and the development of stomach cancer.[5]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "Lodoxamide Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 24 November 2021.
  2. 2.0 2.1 2.2 2.3 2.4 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1206. ISBN 978-0857114105.
  3. "Lodoxamide ophthalmic (Alomide) Use During Pregnancy". Drugs.com. Archived from the original on 26 November 2020. Retrieved 24 November 2021.
  4. "Lodoxamide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 24 November 2021.
  5. MacKenzie, AE; Caltabiano, G; Kent, TC; Jenkins, L; McCallum, JE; Hudson, BD; Nicklin, SA; Fawcett, L; Markwick, R; Charlton, SJ; Milligan, G (2014). "The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35". Molecular Pharmacology. 85 (1): 91–104. doi:10.1124/mol.113.089482. ISSN 0026-895X. PMC 3868900. PMID 24113750.

External links

Identifiers: